

RECEIVED
CENTRAL FAX CENTER

DEC 08 2006

I hereby certify that this paper along with the following documents are being facsimile transmitted to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date: December 8, 2006

VICKI COLLINS
Type or print name of person signing certification
Vicki Collins
Signature of person signing certification

Attorney Docket No. 270.PFUS
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dahl et al.

Serial No.: 10/540,794

Group No.: unassigned

Filed: March 20, 2006

Examiner Pryor, Alton N.

For: COMPOSITION AND METHODS FOR COMBINATION ANTIVIRAL THERAPY

Commissioner for Patents
Mail Stop Missing Parts
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement.

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ FORM PTO - 1449 (Modified)
3. ☐ Identification of Prior Application in Which Listed Information Was Already Cited.

Section 1.

Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose. To the extent that this submission includes an International Search Report, such Report is submitted to facilitate the Examiner's analysis of the references and not out of any belief that the International Searching Authority's construction of the relevance of the references has any bearing under United States Law.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

BEST AVAILABLE COPY


Section 3. Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

This application relies, under 35 U.S.C. 120, at least on the earlier filing dates of prior applications:

Copies of references are not supplied to the extent that they are found in the file history of the prior application(s). Copies of references that were not supplied in the prior application(s), if any, accompany this paper.

Reg. No. 27,043

Tel. No.: (650) 522-5535



SIGNATURE OF ATTORNEY
Max Hensley

Type or print name of attorney
Gilead Sciences, Inc.
333 Lakeside Drive

P.O. Address
Foster City, CA 94404

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(37 CFR 1.98(b))</small>	ATTY DOCKET NO.: 270.PFUS SERIAL NO.: 10/540794	
	APPLICANT: Dahl et al	
	FILING DATE: 3/20/2006	GROUP ART UNIT: 1616
	EXAMINER NAME:	
Sheet 1 of 1		RECEIVED CENTRAL FAX CENTER

DEC 08 2006

U.S. PATENT DOCUMENTS					
Examiner initials	Cite No	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS				
Examiner initials	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
		GILEAD SCIENCES, INC., "Gilead Sciences to Acquire Triangle Pharmaceuticals for \$464 Million" Gilead to Launch Coviracil in 2003 Will Develop Co-Formulation of Viread and Coviracil", Press Release, 2002		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

BEST AVAILABLE COPY